third-line treatment

You have access
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
TOMOHIRO MATSUO, YASUYOSHI MIYATA, JUNKI HARADA, ITSUHO ITOH, TSUYOSHI MATSUDA, AKIHIRO ASAI, TSUBASA KONDO, HIROKI KURATA, SUZUNA SAKAI, HIDENORI ITOH, KENSUKE MITSUNARI and RYOICHI IMAMURA

Anticancer Research June 2025, 45 (6) 2563-2573; DOI: https://doi.org/10.21873/anticanres.17628
You have access
Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer
TARO SATO, HIROKI OSUMI, EIJI SHINOZAKI, AKIRA OOKI, KEITARO SHIMOZAKI, DAISAKU KAMIIMABEPPU, IZUMA NAKAYAMA, TAKERU WAKATSUKI, MARIKO OGURA, DAISUKE TAKAHARI, KEISHO CHIN and KENSEI YAMAGUCHI

Anticancer Research August 2021, 41 (8) 3905-3915; DOI: https://doi.org/10.21873/anticanres.15186
You have access
Risk–benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer
MICHIO KIMURA, EISEKI USAMI, HITOMI TERAMACHI and TOMOAKI YOSHIMURA

Anticancer Research June 2021, 41 (6) 3091-3097; DOI: https://doi.org/10.21873/anticanres.15093
You have access
Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer
MICHIO KIMURA, EISEKI USAMI, HITOMI TERAMACHI and TOMOAKI YOSHIMURA

Anticancer Research March 2020, 40 (3) 1605-1611; DOI: https://doi.org/10.21873/anticanres.14108

Main menu

User menu

Search

third-line treatment